Phase 2 study of TC-5214 for resistant hypertension

Targacept announced the initiation of a Phase 2 exploratory study of TC-5214 for the treatment of resistant hypertension. This study is a double-blind, placebo-controlled trial of approximately 12 subjects with resistant hypertension.  Patients will receive either a single escalating dose of TC-5214 or placebo once per week for four weeks, followed by a fixed daily dose of TC-5214 or placebo over the next two weeks.

TC-5214 is an investigational nicotinic channel blocker being studied as augmentation therapy for treatment-resistant hypertension.  

For more information call (336) 480-2100 or visit